Abstract
20(S)-Camptothecin exists in equilibrium between its lactone (CPT) and its carboxylate forms (Na-CPT) under simulated physiological conditions, with the equilibrium favoring the carboxylate form. The rates of lactone hydrolysis were studied in plasma, serum albumin, and blood and were found to be faster than in aqueous buffers at equivalent pH values. From mechanistic information and in vivo activity data, the lactone appears to be the active form of the drug. It has been argued, therefore, that if an equilibrium existed between the lactone and the carboxylate, Na-CPT could be used to deliver the lactone effectively. In the present study, plasma pharmacokinetics were performed in sodium pentobarbital-anesthetized rats treated with both CPT (lactone) and the sodium salt of camptothecin (carboxylate, Na-CPT) and the lactone and carboxylate, as well as the total drug, concentration versus time profiles were assessed. It was found that plasma concentrations and AUC values for the lactone were significantly higher after dosing with CPT than after dosing with Na-CPT. After i.v. administration, the ratio of plasma lactone to carboxylate was skewed by the apparent rapid and extensive uptake of the lactone into tissues and the rapid clearance of both species. From our results, it appears that the lower in vivo activity of Na-CPT compared to that from CPT administration might be attributed to the altered conversion of carboxylate into lactone in vivo compared to that predicted from in vitro data.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
M. E. Wall, M. C. Wani, C. E. Cook, K. H. Palmer, A. T. McPhail, and G. A. Sims. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc. 88:3888–3890 (1966).
M. C. Wani, P. E. Ronman, J. T. Lindley, and M. E. Wall. Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogs. J. Med. Chem. 23:554–560 (1980).
R. P. Hertzberg, M. J. Caranfa, and S. M. Hecht. On the mechanism of Topoisomerase I inhibition by camptothecin; evidence for binding to enzyme-DNA complex. Biochemistry 29:4629–4638 (1989).
J. C. Wang. DNA Topoisomerases. Annu. Rev. Biochem. 54:665–697 (1985).
C. Jaxel, K. W. Kohn, M. C. Wani, M. E. Wall, and Y. Pommier. Structure-activity study of the actions of camptothecin derivatives of mammalian Topoisomerase I; Evidence for a specific receptor site and a relation to antitumor activity. Cancer Res 49:1465–1469 (1989).
Y. Hsiang, L. F. Liu, M. E. Wall, M. C. Wani, A. W. Nicholas, G. Manikumar, S. Kirscenbaum, R. Silber, and M. Potmesil. DNA Topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res. 49:4385–4389 (1989).
L. F. Liu. DNA Topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351–375 (1989).
J. A. Gottlieb, and J. K. Luce. Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep. 56:103–105 (1972).
F. M. Muggia, P. J. Creaven, H. H. Hansen, M. H. Cohen, and O. S. Selawry. Phase I clinical trial of weekly and daily treatment with camptothecin; Correlation with preclinical studies. Cancer Chemother. Rep. 56:515–521 (1972).
P. J. Creaven, L. M. Allen, and F. M. Muggia. Plasma camptothecin (NSC-100880) levels during a 5 day course of treatment. Cancer Chemother. Rep. 56:573–578 (1972).
M. E. Wall and M. C. Wani. Antineoplastic agents from plants. Annu. Rev. Pharmacol. Toxicol. 17:117–132 (1977).
R. P. Hertzberg, M. J. Caranfa, K. G. Holden, D. R. Jakas, G. Gallagher, M. R. Mattern, S. M. Mong, J. O. Bartus, R. K. Johnson, and W. D. Kingsbury. Modification of hydroxy lactone ring of camptothecin; Inhibition of mammalian Topoisomerase I and biological activity. J. Med. Chem. 32:715–720 (1989).
P. J. Creaven, and L. M. Allen. Renal clearance of camptothecin (NSC-100880); Effect of urine volume. Cancer Chemother. Rep. 57:175–184 (1973).
J. P. Loh and A. E. Ahmed. Determination of camptothecin in biological fluids using reversed-phase high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 530:367–376 (1990).
J. Fassberg and V. J. Stella. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J. Pharm. Sci. 81:676–684 (1992).
J. G. Supko, and L. Malspeis. A reversed-phase HPLC method for determining camptothecin in plasma with specificity for the intact lactone form of the drug. J. Liq. Chromatogr. 14:1779–1803 (1991).
J. H. Beijnen, B. R. Smith, W. J. Keijer, R. V. Gijn, W. W. Ten Bokkel Huinink, L. Th. Vlasveld, S. Rodenhuis, and W. J. M. Underberg. High performance liquid chromatographic analysis of the new antitumor drug SKF 104864-A (NSC-609699) in plasma. J. Pharm. Biomed. Anal. 8:789–794 (1990).
J. G. Supko and L. Malspeis. Pharmacokinetics of camptothecin, 9-aminocamptothecin and 10,11-methylenedioxycamptothecin in the mouse. Proc. Am. Assoc. Cancer Res. 32: 2049 (1991).
J. G. Supko, J. Plowman, D. J. Dykes, and D. S. Zaharko. Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokinetics. Proc. Am. Assoc. Cancer Res. 33:2578 (1992).
P. L. Smith, J. G. Liehr, S. Jacob, A. E. Ahmed, H. R. Hinz, J. Mendoza, A. Kozielski, J. S. Stehlin, and B. C. Giovanella. Pharmacokinetics of tritium labeled camptothecin in nude mice. Proc. Am. Assoc. Cancer Res. 33:2579 (1992).
A. M. Guarino, J. B. Anderson, D. K. Starkweather, and C. F. Chignell. Pharmacologic studies of camptothecin (NSC-100880); Distribution, plasma protein binding and biliary excretion. Cancer Chemother. Rep. 57:125–140 (1973).
H. Cheng and J. J. Jusko. Mean interconversion times and distribution rate parameters for drugs undergoing reversible metabolism. Pharm. Res. 7:1003–1010 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scott, D.O., Bindra, D.S. & Stella, V.J. Plasma Pharmacokinetics of the Lactone and Carboxylate Forms of 20(S)-Camptothecin in Anesthetized Rats. Pharm Res 10, 1451–1457 (1993). https://doi.org/10.1023/A:1018919224450
Issue Date:
DOI: https://doi.org/10.1023/A:1018919224450